The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients

Completed · Phase 1

Conditions studied: HIV Infections

In brief

To study the safety, tolerance, single and multiple dose pharmacokinetics, and anti-HIV activity of bis-POM PMEA ( adefovir dipivoxil ) versus placebo when administered orally on a daily basis for 2 weeks to HIV-infected patients.

Key facts

Study ID
NCT00002346
Run by
Gilead Sciences
People needed
36
Last updated by the study team
2005-06-24

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.